サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468062

アルファエミッター市場レポート：核種別、医療用途別、エンドユーザー別、地域別、2024～2032年

Alpha Emitter Market Report by Type of Radionuclide, Medical Application, End User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 136 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
アルファエミッター市場レポート：核種別、医療用途別、エンドユーザー別、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アルファエミッターの世界市場規模は2023年に14億7,680万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに109億7,580万米ドルに達し、2024～2032年の間に24.22%の成長率（CAGR）を示すと予測しています。

アルファエミッターは、アルファ粒子を放出した後に崩壊する放射源から放出される物質です。適切な生体内分布とそれに伴う線量分布を達成することで、許容できない急性・長期の副作用を引き起こすことなく、効果的な治療を実現します。非常に高い殺細胞率を持つアルファ粒子は、医療処置に使用される場合、ベータ粒子よりも腫瘍細胞に対する破壊力が強いです。その結果、隣接する正常組織へのダメージが少ないです。治療過程で使用される核種には、ラジウム、鉛、ビスマスなどがあります。アルファ粒子は飛程が短く、線エネルギー付与（LET）が高いため、医療研究、特にがんの治療法として非常に魅力的です。卵巣がん、膵臓がん、リンパ腫、メラノーマなど、アルファエミッターで治療できるがんの種類は数多くあります。

アルファエミッターの市場動向：

市場は、がん治療において行われている広範かつハイエンドの研究開発（R&D）活動によって大きく牽引されています。この背景には、標的αエミッターの殺細胞能力に関する意識の高まりがあります。これに伴い、大衆の間でさまざまな種類のがんの有病率が上昇していることも、市場に弾みをつけています。また、多くの心臓疾患やがんを発症しやすい高齢者人口が増加していることも、市場に明るい展望をもたらしています。さらに、医療施設における標的抗がん剤やアルファ線療法（TAT）の採用が増加していることも、市場にプラスの影響を与えています。さらに、継続的な技術の進歩や核医療別の新製品の承認数の増加も市場を後押ししています。その他、急速な都市化、医療インフラの継続的な改善、医療費の増加、個人の可処分所得水準の上昇なども市場に寄与しています。

本レポートで扱う主要質問

  • 2023年のアルファエミッター世界市場規模は？
  • 2024～2032年のアルファエミッター世界市場の予想成長率は？
  • アルファエミッターの世界市場を牽引する主要因は？
  • COVID-19がアルファエミッターの世界市場に与えた影響は？
  • 核種別のアルファエミッターの世界市場の内訳は？
  • 医療用途別のアルファエミッター世界市場の内訳は？
  • アルファエミッターの世界市場の主要地域は？
  • アルファエミッターの世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 アルファエミッターの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：核種別

  • アスタチン
  • ラジウム
  • アクチニウム
  • 鉛
  • ビスマス
  • その他

第7章 市場内訳：医療用途別

  • 前立腺がん
  • 骨転移
  • 卵巣がん
  • 膵臓がん
  • 内分泌腫瘍
  • その他

第8章 市場内訳：エンドユーザー別

  • 病院
  • 医療研究機関
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Actinium Pharmaceuticals Inc.
    • Alpha Tau Medical Ltd.
    • Bayer AG
    • Fusion Pharmaceuticals
    • IBA RadioPharma Solutions
    • RadioMedix Inc.
図表

List of Figures

  • Figure 1: Global: Alpha Emitter Market: Major Drivers and Challenges
  • Figure 2: Global: Alpha Emitter Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Alpha Emitter Market: Breakup by Type of Radionuclide (in %), 2023
  • Figure 5: Global: Alpha Emitter Market: Breakup by Medical Application (in %), 2023
  • Figure 6: Global: Alpha Emitter Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Alpha Emitter Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Alpha Emitter (Astatine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Alpha Emitter (Astatine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Alpha Emitter (Radium) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Alpha Emitter (Radium) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Alpha Emitter (Actinium) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Alpha Emitter (Actinium) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Alpha Emitter (Lead) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Alpha Emitter (Lead) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Alpha Emitter (Bismuth) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Alpha Emitter (Bismuth) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Alpha Emitter (Other Type of Radionuclides) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Alpha Emitter (Other Type of Radionuclides) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Alpha Emitter (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Alpha Emitter (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Alpha Emitter (Bone Metastasis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Alpha Emitter (Bone Metastasis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Alpha Emitter (Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Alpha Emitter (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Alpha Emitter (Pancreatic Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Alpha Emitter (Pancreatic Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Alpha Emitter (Endocrine Tumors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Alpha Emitter (Endocrine Tumors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Alpha Emitter (Other Medical Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Alpha Emitter (Other Medical Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Alpha Emitter (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Alpha Emitter (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Alpha Emitter (Medical Research Institutions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Alpha Emitter (Medical Research Institutions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Alpha Emitter (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Alpha Emitter (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: North America: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: North America: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: United States: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: United States: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Canada: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Canada: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Asia-Pacific: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Asia-Pacific: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: China: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: China: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Japan: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Japan: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: India: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: India: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: South Korea: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: South Korea: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Australia: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Australia: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Indonesia: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Indonesia: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Others: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Others: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Europe: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Europe: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Germany: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Germany: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: France: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: France: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: United Kingdom: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: United Kingdom: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Italy: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Italy: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Spain: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Spain: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Russia: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Russia: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Latin America: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Latin America: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Brazil: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Brazil: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Mexico: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Mexico: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Others: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Others: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Middle East and Africa: Alpha Emitter Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Middle East and Africa: Alpha Emitter Market: Breakup by Country (in %), 2023
  • Figure 86: Middle East and Africa: Alpha Emitter Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Global: Alpha Emitter Industry: SWOT Analysis
  • Figure 88: Global: Alpha Emitter Industry: Value Chain Analysis
  • Figure 89: Global: Alpha Emitter Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alpha Emitter Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Alpha Emitter Market Forecast: Breakup by Type of Radionuclide (in Million US$), 2024-2032
  • Table 3: Global: Alpha Emitter Market Forecast: Breakup by Medical Application (in Million US$), 2024-2032
  • Table 4: Global: Alpha Emitter Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Alpha Emitter Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Alpha Emitter Market: Competitive Structure
  • Table 7: Global: Alpha Emitter Market: Key Players
目次
Product Code: SR112024A6398

The global alpha emitter market size reached US$ 1,476.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 10,975.8 Million by 2032, exhibiting a growth rate (CAGR) of 24.22% during 2024-2032.

Alpha emitters are substances emitted by radioactive sources that decay after releasing alpha particles. They achieve appropriate biodistribution and associated dose distribution to achieve effective therapy without causing unacceptable acute or long-term side effects. With their exceptionally high cell-killing rates, alpha particles are more destructive to tumor cells than beta particles when used in medical procedures. Consequently, they cause less damage to adjacent normal tissues. Radium, lead and bismuth are some of the radionuclides used in the treatment process. The short range and high linear energy transfer (LET) of alpha particles have made them remarkably appealing to medical research, particularly as a viable treatment method for cancer. There are numerous types of cancer that can be treated with alpha emitters, including ovarian cancer, pancreatic cancer, lymphoma, and melanoma.

Alpha Emitter Market Trends:

The market is majorly driven by extensive and high-end research and development (R&D) activities being conducted in cancer treatment. This can be attributed to the growing awareness regarding the cell-killing abilities of targeted alpha emitters. In line with this, the rising prevalence of various types of cancer among the masses is providing an impetus to the market. Also, the increasing geriatric population that is susceptible to develop numerous cardiac and cancer ailments is creating a positive outlook for the market. Moreover, the rising adoption of targeted anticancer or alpha therapy (TAT) in healthcare facilities is impacting the market positively. The market is further propelled by continual technological advancements and the growing number of new nuclear-medicine-based product approvals. Some of the other factors contributing to the market include rapid urbanization, continual improvements in healthcare infrastructure, rising medical expenditure and inflating disposable income levels of the individuals.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global alpha emitter market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type of radionuclide, medical application, and end user.

Breakup by Type of Radionuclide:

Astatine

Radium

Actinium

Lead

Bismuth

Others

Breakup by Medical Application:

Prostate Cancer

Bone Metastasis

Ovarian Cancer

Pancreatic Cancer

Endocrine Tumors

Others

Breakup by End User:

Hospitals

Medical Research Institutions

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions and RadioMedix Inc.

Key Questions Answered in This Report

  • 1. What was the size of the global alpha emitter market in 2023?
  • 2. What is the expected growth rate of the global alpha emitter market during 2024-2032?
  • 3. What are the key factors driving the global alpha emitter market?
  • 4. What has been the impact of COVID-19 on the global alpha emitter market?
  • 5. What is the breakup of the global alpha emitter market based on the type of radionuclide?
  • 6. What is the breakup of the global alpha emitter market based on the medical application?
  • 7. What are the key regions in the global alpha emitter market?
  • 8. Who are the key players/companies in the global alpha emitter market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alpha Emitter Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type of Radionuclide

  • 6.1 Astatine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Radium
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Actinium
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Lead
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Bismuth
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Medical Application

  • 7.1 Prostate Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Bone Metastasis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Ovarian Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pancreatic Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Endocrine Tumors
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Medical Research Institutions
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Actinium Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Alpha Tau Medical Ltd.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Fusion Pharmaceuticals
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 IBA RadioPharma Solutions
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 RadioMedix Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio